XML 36 R27.htm IDEA: XBRL DOCUMENT v3.25.3
Description of Business and Significant Accounting Policies (Tables)
9 Months Ended
Sep. 30, 2025
Accounting Policies [Abstract]  
Schedule of Segment Revenues and Significant Expense Categories in Consolidated Statements of Operations The table below shows the details of the Company’s segment revenues and significant expense categories regularly provided to and reviewed by the CODM as well as other significant segment items included in consolidated net income in the condensed consolidated statements of operations:

 

 

Three Months
Ended September 30,

 

 

Nine Months
Ended September 30,

 

Revenues

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Afrezza

 

$

18,493

 

 

$

15,035

 

 

$

51,709

 

 

$

45,762

 

V-Go

 

 

3,812

 

 

 

4,693

 

 

 

12,023

 

 

 

13,510

 

Collaborations and services

 

 

26,506

 

 

 

23,268

 

 

 

78,727

 

 

 

74,130

 

Royalties

 

 

33,319

 

 

 

27,083

 

 

 

94,552

 

 

 

75,326

 

Total revenues

 

 

82,130

 

 

 

70,079

 

 

 

237,011

 

 

 

208,728

 

Less significant segment expenses (income):

 

 

 

 

 

 

 

 

 

 

 

 

Cost of goods sold – commercial

 

 

4,498

 

 

 

3,197

 

 

 

12,873

 

 

 

12,621

 

Cost of revenue – collaborations and services

 

 

15,705

 

 

 

14,826

 

 

 

45,414

 

 

 

44,377

 

Research and development

 

 

14,063

 

 

 

12,926

 

 

 

38,760

 

 

 

34,755

 

Selling

 

 

14,694

 

 

 

13,093

 

 

 

43,335

 

 

 

36,189

 

General and administrative

 

 

14,394

 

 

 

10,823

 

 

 

42,389

 

 

 

34,168

 

Interest income, net

 

 

(2,628

)

 

 

(3,179

)

 

 

(6,416

)

 

 

(9,790

)

Interest expense, net

 

 

7,334

 

 

 

8,360

 

 

 

24,157

 

 

 

30,500

 

Impairment of available-for-sale investment

 

 

6,409

 

 

 

 

 

 

6,409

 

 

 

1,550

 

Loss on settlement of debt

 

 

 

 

 

 

 

 

 

 

 

7,050

 

Other segment items(1)

 

 

(324

)

 

 

(1,517

)

 

 

8,279

 

 

 

(2,858

)

Consolidated net income

 

$

7,985

 

 

$

11,550

 

 

$

21,811

 

 

$

20,166

 

_________________________

(1) Includes (gain) loss on foreign currency transaction, loss on settlement of debt, loss on available-for-sale securities and income tax (benefit) expense.

Summary of Revenue and Cost of Revenue and Goods Sold Generated From Product Sales, Services and Royalties

The Company’s net revenue as shown on the condensed consolidated statement of operations is comprised of revenue generated from product sales, services and royalties as shown below (in thousands):

 

 

Three Months
Ended September 30,

 

 

Nine Months
Ended September 30,

 

 

 

2025

 

 

2024

 

 

2025

 

 

2024

 

Net revenue:

 

 

 

 

 

 

 

 

 

 

 

 

Product revenue (1)

 

$

48,274

 

 

$

42,959

 

 

$

140,743

 

 

$

132,945

 

Services (2)

 

 

537

 

 

 

37

 

 

 

1,716

 

 

 

457

 

Royalties (3)

 

 

33,319

 

 

 

27,083

 

 

 

94,552

 

 

 

75,326

 

Total net revenue

 

$

82,130

 

 

$

70,079

 

 

$

237,011

 

 

$

208,728

 

_________________________

(1)
Amounts represent the revenue from Afrezza and V-Go sales to wholesalers and specialty pharmacies and Tyvaso DPI to UT.
(2)
Amounts represent revenue generated from the Company's collaboration arrangements. See Note 9 – Collaborations, Licensing and Other Arrangements.
(3)
Amounts represent royalties on UT’s net revenue from Tyvaso DPI sales.